跳到正文
原文
Medical Xpress·· 2026-10-08精选AI 评分63

UCSF 研究显示 lenacapavir 联合 cabotegravir 长效方案在 46 人中维持 HIV 病毒抑制

How a new long-acting HIV drug combo tackles resistance

AI 导读

UCSF 的 Ward 86 HIV 诊所对 46 名使用长效 lenacapavir 联合 cabotegravir 的感染者开展观察,所有人在中位近两年随访中维持 HIV 病毒载量检测不到。

推荐理由

针对尚未获批的长效组合,46 人观察性队列提供了耐药人群的早期用药数据,可与现有获批方案对照理解。

正文
HIV
Credit: Pixabay/CC0 Public Domain

A new long-acting HIV treatment could expand options for people who have trouble taking daily pills and whose virus is resistant to some commonly used HIV drugs, according to a new UC San Francisco study.

Unlike daily HIV pills, long-acting treatments can be given weeks or months apart, which can make it easier for people who struggle to take medication every day. The only approved long-acting combination pairs cabotegravir with rilpivirine. But HIV can develop resistance to rilpivirine and related drugs, limiting its use for some people. Moreover, rilpivirine is not available in low- and middle-income countries.

The new approach replaces rilpivirine with lenacapavir, a long-acting drug that attacks HIV in a different way. In the new study, all the participants achieved and maintained control of the virus.

The findings, published Oct. 8 in JAMA Network Open, could help address an important gap in long-acting HIV treatment.

"Clinicians are already starting to use these two drugs together, and until now we've had very little evidence to guide us," said Monica Gandhi, M.D., M.P.H., senior author of the paper and a UCSF professor of medicine. "This is the largest group studied on this combination, and we think these findings could help providers have more confidence using it."

Researchers at UCSF's Ward 86 HIV Clinic studied 46 people who received long-acting lenacapavir and cabotegravir. Nearly three-quarters had the type of drug resistance that can limit use of the approved combination, and more than half had detectable HIV when they started treatment.

All participants who started with detectable HIV brought the virus under control within 13 weeks, while those who already had it under control stayed that way. After a median follow-up of nearly two years, all participants continued to have undetectable HIV viral loads, the goal of HIV therapy.

The combination is not yet approved as an HIV treatment, and the study did not compare it directly with other treatments. Two clinical trials are planned to study the approach more closely.

But the findings could influence care before those trials are completed. Lenacapavir and cabotegravir are becoming more widely available around the world, including through agreements that allow generic versions in many lower-income countries.

Who's behind this story?

Swati Mestri

Swati Mestri

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Alexander Pol

Alexander Pol

PhD nano-engineering from Delft University. Published researcher and journal reviewer. Brings scientific insight to content standards. Full profile →

Citation: How a new long-acting HIV drug combo tackles resistance (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-hiv-drug-combo-tackles-resistance.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com